Just one month after the US Food and Drug Administration (FDA) vouched for Biogen's drug Aduhelm for treating Alzheimer's disease, the authority has adjusted the prescribing information for this medication, which changes the patients that the drug should be recommended to.
Biogen took the initiative to this drug on the basis of conversations, which Biogen representatives have had with doctors after the approval.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.